Day One Biopharmaceuticals Inc Cash Flow Conversion Efficiency
Day One Biopharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Day One Biopharmaceuticals Inc (DAWN) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.80 Million) by net assets ($450.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Day One Biopharmaceuticals Inc (2019–2024)
Cash flow conversion efficiency of Day One Biopharmaceuticals Inc from 2019 to 2024. This chart illustrates how Day One Biopharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Day One Biopharmaceuticals Inc for real-time trading data and today's change.
Day One Biopharmaceuticals Inc Cash Flow Conversion Ratio Explained
Day One Biopharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Day One Biopharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Day One Biopharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Day One Biopharmaceuticals Inc (DAWN) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Parade Technologies Ltd
TWO:4966
|
0.024x |
|
Playtech plc
F:PL8
|
0.082x |
|
Nokian Renkaat Oyj
HE:TYRES
|
0.015x |
|
Shenzhen Mason Technologies Co Ltd
SHE:002654
|
0.155x |
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
0.000x |
|
Yunnan Salt & Salt Chemical Industry Co Ltd
SHE:002053
|
0.031x |
|
Elan Microelectronics Corp
TW:2458
|
0.095x |
|
U-Haul Holding Company
NYSE:UHAL
|
0.031x |
Annual Cash Flow Conversion Efficiency for Day One Biopharmaceuticals Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Day One Biopharmaceuticals Inc from 2019 to 2024. Review Day One Biopharmaceuticals Inc (DAWN) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $502.75 Million | $-78.11 Million | -0.155x | +63.34% |
| 2023-12-31 | $346.54 Million | $-146.85 Million | -0.424x | -28.06% |
| 2022-12-31 | $332.04 Million | $-109.87 Million | -0.331x | -91.67% |
| 2021-12-31 | $281.15 Million | $-48.54 Million | -0.173x | +44.37% |
| 2020-12-31 | $43.46 Million | $-13.49 Million | -0.310x | -135.65% |
| 2019-12-31 | $-5.19 Million | $-4.51 Million | 0.871x | -- |
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory… Read more